$38.1 Million is the total value of venBio Partners LLC's 3 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | New | APELLIS PHARMACEUTICALS INC | $23,611,000 | – | 1,790,102 | +100.0% | 62.01% | – |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $8,444,000 | – | 875,000 | +100.0% | 22.18% | – |
| MNLO | New | MENLO THERAPEUTICS INC | $6,022,000 | – | 1,461,552 | +100.0% | 15.82% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-26
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
| AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
| HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
| APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
| PHARVARIS N V | 11 | Q3 2023 | 25.2% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
| ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
| PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.